Zydus Lifesciences rises on getting USFDA’s final nod for Eltrombopag Tablets [Healthcare]
AI Summary1 min read
TL;DR
Zydus Lifesciences' stock rises after receiving final USFDA approval for Eltrombopag Tablets, reinforcing its position as a leading Indian pharmaceutical innovator focused on quality and affordability.
Tags
Pharmaceuticals & DrugsHealthcareZydus LifesciencesUSFDA approvalEltrombopag Tabletspharmaceuticalsstock rise
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. The company is committed to deliver high quality, affordable medicines to the patients by leveraging the best contemporary technology and process improvements.